CROs to prosper under Democratic Congress?
A recent report from UPI seems to suggest that contract research organizations (CROs) will prosper under the new democratically controlled congress.
United Press International - Health Business - Analysis: CROs may prosper under Democrats:
Their reasoning confuses me. James Kumpel, an analyst with Friedman, Billings and Ramsey states that these organizations will thrive since safety is likely to be a focus. They then mention three companies; PPDI, Covance and eResearchTechnology. What I fail to understand is how using a 3rd party contractor makes the drug development process inherently safer? I understand that if electronic filing of clinical data is required that some companies may benefit but I don’t see how safety is improved. The reasoning is vague at best in this article and it may be that these investment firms have a interest in seeing these companies do well.
I’ll have another post later on my general ideas of how the new congress may effect the pharmaceutical industry.
Technorati Tags: Congress, drug safety
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
